← Leaderboards
Vladimir Ponomarev
Sloan-Kettering Institute For Cancer Res
$13,434,344
Attributed
$19,857,274
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,857,274 · 13
By mechanism
R01$17,822,816 · 8
R21$1,321,076 · 3
P50$703,382 · 1
R13$10,000 · 1
Top collaborators
- Ronald G Blasberg11 shared
- Goutam Chakraborty5 shared
- Nagavarakishore Pillarsetty5 shared
- Jan Grimm3 shared
- Prasad S. Adusumilli2 shared
- Joaquin Lopez Herraiz2 shared
- Heiko Schoder2 shared
- Jose Manuel Udias Moinelo2 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Ronald G Blasberg$11,404,709
- George Sgouros$17,275,548
- Michael J Morris$6,941,101
- Lawrence H Schwartz$9,739,750
- Paul J Sabbatini$3,542,584
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorImageResponseImmunotherapyT-LymphocytePositron-Emission TomographyMalignant Neoplasm Of ProstateMonitorCancer PatientTraffickingProstateCellsClinicTranslatingClinical TrialsSignal TransductionReporterT Cell TherapyPre-ClinicalBaseImmune ResponseT-Cell ActivationClinical ResearchAntigens
Grant awards (44)
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$722,240
R01 · FY2025 · CA
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy$699,311
R01 · FY2025 · CA · contact PI
Multicolor PET to interrogate cancer biology$673,118
R01 · FY2025 · EB
Bispecific antibodies in multiple myeloma: understanding therapy resistance through imaging$452,540
R21 · FY2025 · CA · contact PI
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$135,585
R01 · FY2025 · CA
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy$720,416
R01 · FY2024 · CA · contact PI
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$678,271
R01 · FY2024 · CA
Multicolor PET to interrogate cancer biology$627,848
R01 · FY2024 · EB
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$114,678
R01 · FY2024 · CA
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$729,450
R01 · FY2023 · CA
Multicolor PET to interrogate cancer biology$659,909
R01 · FY2023 · EB
World Molecular Imaging Congress$10,000
R13 · FY2023 · EB · contact PI
Image-guided TRAIL-enhanced CAR T-cell immunotherapy$565,587
R01 · FY2022 · CA · contact PI
Image-guided TRAIL-enhanced CAR T-cell immunotherapy$577,130
R01 · FY2021 · CA · contact PI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy$768,857
R01 · FY2020 · CA · contact PI
Image-guided TRAIL-enhanced CAR T-cell immunotherapy$567,760
R01 · FY2020 · CA · contact PI
Secretable theranostic payloads to augment the efficacy of adoptive CAR-T cell therapies$455,112
R21 · FY2020 · CA · contact PI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy$668,089
R01 · FY2019 · CA
Image-guided TRAIL-enhanced CAR T-cell immunotherapy$529,039
R01 · FY2019 · CA · contact PI
Enhancement of T cell therapy by incorporating adjunct treatment strategies$80,105
R01 · FY2019 · CA
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy$657,305
R01 · FY2018 · CA
Image-guided TRAIL-enhanced CAR T-cell immunotherapy$625,160
R01 · FY2018 · CA · contact PI
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy$187,920
R21 · FY2018 · CA · contact PI
Enhancement of T cell therapy by incorporating adjunct treatment strategies$23,150
R01 · FY2018 · CA
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy$669,635
R01 · FY2017 · CA
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy$225,504
R21 · FY2017 · CA · contact PI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy$645,363
R01 · FY2016 · CA
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival$470,514
R01 · FY2016 · CA
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival$505,733
R01 · FY2015 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy$379,518
R01 · FY2015 · CA · contact PI
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival$503,520
R01 · FY2014 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy$368,132
R01 · FY2014 · CA · contact PI
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival$490,230
R01 · FY2013 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy$356,747
R01 · FY2013 · CA · contact PI
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival$520,680
R01 · FY2012 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy$379,518
R01 · FY2012 · CA · contact PI
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy$372,861
R01 · FY2011 · CA · contact PI
PET Imaging of Genetically Modified Human T-Cells in Prostate Cancer$276,091
P50 · FY2010 · CA · contact PI
PET Imaging of Genetically Modified Human T-Cells in Prostate Cancer$276,091
P50 · FY2009 · CA · contact PI
PET Imaging of Tumor Targeting & Role of T Lymphocytes$341,948
R01 · FY2008 · CA · contact PI
PET Imaging of Genetically Modified Human T-Cells in Prostate Cancer$151,200
P50 · FY2008 · CA · contact PI
PET Imaging of Tumor Targeting & Role of T Lymphocytes$341,948
R01 · FY2007 · CA · contact PI
PET Imaging of Tumor Targeting & Role of T Lymphocytes.$322,846
R01 · FY2006 · CA · contact PI
PET Imaging of Tumor Targeting &Role of T Lymphocytes$330,615
R01 · FY2005 · CA